In recent years, new drugs called “biosimilars” have become available in the United States, and in the summer of 2023 at least eight new competitors to adalimumab (Humira) will be introduced. This article from the Arthritis Foundation explains how these new biologic drugs compare with existing ones, and addresses whether biosimilars should be taken during pregnancy or breastfeeding.
Biosimilar Safety in Pregnancy
0
Share.
